February 2024

Data shed light on brentuximab vedotin plus nivolumab, bendamustine, or gemcitabine.

Precision oncology represents an evolution in therapeutic practice.

These combination therapies have demonstrated longer PFS with a tolerable AE profile.

Certain patients may present asymptomatically, affecting treatment options.

The pharmacist’s role may vary across different practices and institutions.

Tucatinib significantly improved median PFS in the overall population and those with brain metastases.

The complexity of the disease and number of treatment options can necessitate a personalized approach.

The oral therapy is available through a REMS program.

This frequency can allow for faster observation of toxicities and adherence issues.

This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.

These disorders can be fatal, making pharmacists’ role in detection crucial.

Treatment options are distinct in their mechanisms, safety profiles, and implications for patients’ quality of life.

This issue of Pharmacy Practice in Focus: Oncology features the publication's first manuscript to undergo peer review.

"Pharmacy Practice in Focus: Oncology" welcomes the launch of the peer-review process.